InMode Ltd. Announces Exercise of Over-Allotment Option

LAKE FOREST, Calif., Aug. 20, 2019 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode") announced today the issuance and sale of an additional 500,000 ordinary shares pursuant to the partial exercise of the underwriters' over-allotment option in connection with InMode's initial public offering. The additional shares were sold at the initial offering price of $14.00 per ordinary share, generating additional gross proceeds of approximately $7.0 million and bringing the total gross proceeds to InMode from the offering, before deducting underwriting discounts and commissions and other offering expenses, to approximately $77.0 million.

Barclays Capital Inc. and UBS Investment Bank acted as the representatives of the underwriters and joint book-running managers for the offering. Canaccord Genuity LLC acted as lead manager for the offering. Robert W. Baird & Co. Incorporated acted as co-manager for the offering.

A registration statement related to the offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). The offering was made only by means of a prospectus, copies of which can be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected], or by telephone at (888) 603-5847; or UBS Investment Bank, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275, or by email at [email protected].  SEC filings are available to the public from the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About InMode

InMode Ltd. is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio-frequency (RF) technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.

Forward-Looking Statements 

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or our future financial or operating performance. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements contained in the prospectus related to the offering. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release.

Investor Relations Contact:

Miri Segal
MS-IR LLC
917-607-8654
[email protected]

SOURCE InMode